周五（10月10日），A股、港股市场同频震荡，沪指失守3900点，创指大跌4.55%，恒生指数收出5连 阴。大盘承压，AH医药板块全线走低。 A股医疗板块低开低走，CXO跌幅靠前，巨头药明康德领跌7.2%，规模最大医疗ETF（512170）场内跌 2.03%止步三连阳，盘中下穿3根均线，交投仍在高位，全天成交6.4亿元。拉长时间看，近期医疗板块 走势整体震荡上行，短线回调或无碍趋势走向，作为低位板块，补涨机遇仍值得关注。 | | 分时 卷日 1分 5分 15分 30分 · | | | | F9 盘前盘后 露加 九列 面线 工具 @ (2 ) | | | | | | METF (D) | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1.136 | | | 562050]的ETF] 15:00 价 1.105 源庆 -0.012(-1.07%) 均价 1.110 成交盘 0 IOPY 1 | | | | | 1.105 -0.012 -1.07% | | | | | | 1.130 | | ...

周五（10月10日），A股、港股市场同频震荡，沪指失守3900点，创指大跌4.55%，恒生指数收出5连 阴。大盘承压，AH医药板块全线走低。 A股医疗板块低开低走，CXO跌幅靠前，巨头药明康德领跌7.2%，规模最大医疗ETF（512170）场内跌 2.03%止步三连阳，盘中下穿3根均线，交投仍在高位，全天成交6.4亿元。拉长时间看，近期医疗板块 走势整体震荡上行，短线回调或无碍趋势走向，作为低位板块，补涨机遇仍值得关注。 A股制药板块相对抗跌，主要系中药股逆市飘红，华润三九、吉林敖东涨逾2.5%，创新药则跌多涨少， 百济神州-U领跌6.2%。全市场唯一药ETF（562050）重仓创新药，兼顾中药，场内收跌1.07%，水下区 间溢价走高，反映低吸资金涌动，上日已有223万元资金逢跌加码。 | 分时 6日 1分 5分 15分 30分 · | | | | | | F9 盘前盘后 露加 九排 面线 工具 @ 1 > | | | | | | METF (D) | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | - ...

周四（9月25日），AH市场主要股指分化，医药板块共振回暖。 A股方面，恒瑞医药、百利天恒等创新药龙头领涨制药板块，全市场唯一药ETF（562050）成功续涨； 两大医疗龙头迈瑞医疗、药明康德发力助攻，规模最大医疗ETF（512170）场内逆市涨0.78%两连阳。 | (435 | 名称 | 涨跌幅 | | 两日图 | | --- | --- | --- | --- | --- | | 562050 | GETF | 0.35% | 5 | Product | | 512170 | 医疗ETF | 0.78% | STATE AND THE FORM OF THE FORM OF THE FORM OF THE FOR | 10 | 港股通创新药板块全天红盘震荡，高人气港股通创新药ETF（520880）盘初一度冲高1.6%，场内最终收 涨0.48%终结两连跌，放量成交3.05亿元。场内延续溢价交易状态，显示买盘资金依然强势。 37只成份股涨跌参半，云顶新耀、君实生物领涨超4%，MIRXES-B、博安生物调整居前。多只权重股 收红，百济神州、康方生物涨逾1%。BD大单加持，恒瑞医药港股涨2.57%。 二级市场方 ...

Group 1 - A-shares in the innovative drug sector experienced a strong rebound, with the only drug ETF (562050) rising by 2.18%, ending a three-day decline [1][5] - Key stocks such as Ganli Pharmaceutical and Xinlitai reached their daily limit up, with Ganli Pharmaceutical's stock price hitting a historical high [1][5] - The medical device sector also showed recovery, with the largest medical ETF (512170) increasing by 1.58%, ending a four-day decline [1][5] Group 2 - The Hong Kong innovative drug sector continued to show weakness, with major stocks like Kangfang Biotech and Sanofi falling over 2%, and the Hong Kong innovative drug ETF (520880) declining by 0.64% [3][5] - Despite the mixed performance, the overall sentiment remains positive, driven by multiple favorable factors including significant agreements and policy support [5][6] - Ganli Pharmaceutical signed a 3 billion yuan supply framework agreement for insulin in Brazil, and Xinlitai made substantial progress with its innovative drug pipeline [5][6] Group 3 - The upcoming peak period for innovative drug business development transactions is expected to bring significant deals in October and November [6] - Fund managers maintain a positive outlook on the pharmaceutical sector, suggesting a balanced investment strategy across various segments including medical devices and services [6][7] - The medical ETF market remains robust, with the largest medical ETF (512170) having a scale of 26.5 billion yuan, indicating strong investor interest [8]

9月24日午后，制药板块继续上攻，全市场唯一药ETF（562050）冲高逾2%。 成份股方面，创新药概念领涨，信立泰和甘李药业双双涨停封板！权重股恒瑞医药、百济神州等均飘 红。中药股亦表现不俗，太极集团、东阿阿胶、达仁堂集体涨超2%。 | 分时 多日 1分 5分 · | | | | F9 盘前盘后 露加 九井 画线 工具 @ (2) > | | | | | | | GETF 1 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1,127 | | | 562050[药ETF] 14:06 价 1.127 温康 0.024(2.18%) 均价 1.117 成交盘 .. | | | 1 2.18% | | 1.127 | +0.024 +2.18% | | EGONED 7 | | | 1,119 | | | WAND W | | | 1,45% | | SSE CNY 14:06:07 交易中 | | | | 1 . 4 | | | | | | | | | 净值出现 | | 华富中证制药ET ...

9月24日早盘，制药板块强势反弹，场内唯一药ETF（562050）持续走高上涨1.72%。 药ETF（562050）被动跟踪中证制药指数，该指数前十大权重股分别为恒瑞医药、片仔癀、云南白药、 科伦药业、华东医药、新和成、复星医药、长春高新、百济神州、博瑞医药。 | | | 医药板块怎么投? | | | --- | --- | --- | --- | | 投什么 | 只投创新药! | 投制药龙头! | 投医疗龙头! | | 选什么 | 港股通创新药ETF (520880) | 药ETF (562050) | 医疗ETF (512170) | | | 场外联接基金:025221 | 场外联接基金:024986 | 场外联接基金:012323 | | 最大特点 | 100%创新药研发!港股高弹性,t+0 | 全市场唯一品种* | 规模265亿元,全市场最大 | | 度层资产 | 100%创新药研发类公司 | 重仓创新药,兼顾中药 | 医疗器械+医疗服务(CXO) | | 有无CXO | 无CXO | 无CXO | 有CXO(权重占比25%) | | 庞份股构成 | 全部港股 | 全部A股 | 全部A股 | | | ...

Group 1 - The A-share pharmaceutical sector showed recovery with significant gains in innovative drugs and traditional Chinese medicine, highlighted by Ganli Pharmaceutical's strong performance and a supply agreement worth no less than 3 billion yuan with a Brazilian company [1] - The largest medical ETF in A-shares saw a rebound, with notable increases in CXO concept stocks and medical consumables, indicating a recovery in the medical sector [3] - The Hong Kong stock market displayed mixed performance in innovative drugs, with some leading stocks rising while others fell, reflecting a volatile market environment [5] Group 2 - The fund manager of the Hong Kong Innovation Drug ETF expressed optimism about the CXO sector and the potential for a mid-term rotation towards large-cap blue-chip companies, while cautioning about the performance of small-cap companies [6] - The medical ETF market is dominated by the medical ETF (512170) with a scale of 26.5 billion yuan, making it the largest in the sector, while the drug ETF is the only one tracking the CSI Pharmaceutical Index [8] - The Hong Kong Innovation Drug ETF is designed to passively track the Hang Seng Hong Kong Innovation Drug Select Index, which has shown negative annual returns since its inception, indicating potential challenges ahead [9]

Core Viewpoint - The pharmaceutical sector in both A-shares and Hong Kong stocks experienced significant declines, particularly in innovative drugs and CXO concepts, despite a slight recovery towards the end of the trading session [1][3]. A-Share Market Summary - The largest medical ETF in A-shares (512170) fell by 1.81%, marking its fourth consecutive decline, with a trading volume increase of over 50% to 846 million yuan [1]. - The pharmaceutical sector remained sluggish, with both innovative drugs and traditional Chinese medicine concepts declining, as evidenced by the only drug ETF (562050) dropping 1.61% for three consecutive days [1]. Hong Kong Market Summary - In the Hong Kong market, the innovative drug ETF (520880) saw a decline of 1.42% after a brief rebound, with a trading volume of 327 million yuan [3]. - Among the 37 constituent stocks of the Hong Kong innovative drug ETF, 31 stocks fell, with the largest drop being 5.12% for Yimeng Biotechnology [3]. Market Dynamics - Despite the downturn, both the A-share medical ETF and the Hong Kong innovative drug ETF are trading at a premium, indicating an influx of capital seeking to buy at lower prices [6]. - The Hong Kong innovative drug ETF has attracted nearly 680 million yuan over 14 consecutive trading days from September 2 to 19 [6]. Policy and Industry Outlook - The National Healthcare Security Administration recently released the 11th batch of centralized drug procurement documents, emphasizing quality assurance and reasonable profit margins for pharmaceutical companies [6]. - The fund manager of the Hong Kong innovative drug ETF believes that the new procurement policies will support innovation in the pharmaceutical sector and enhance the industry's profitability [6]. Investment Strategy - The fund manager suggests a potential rotation towards large-cap blue-chip companies in the mid-term, while small-cap companies may lose investor interest if they fail to deliver performance [7]. - A balanced investment approach is recommended, combining innovative drugs with sectors like medical devices and healthcare services [7]. ETF Characteristics - The Hong Kong innovative drug ETF (520880) focuses exclusively on innovative drug research and development, while the medical ETF (512170) includes a broader range of healthcare sectors [8]. - The medical ETF is the largest in the market, with a scale of 26.5 billion yuan, while the drug ETF is the only one tracking the China Pharmaceutical Index [9].

Core Viewpoint - The innovative drug sector is currently experiencing a phase of adjustment, with significant fluctuations in stock prices and ongoing capital inflows into the market [1][3][5]. Group 1: Market Performance - On September 19, A-share market saw a decline in innovative drug stocks, with Kanghong Pharmaceutical down 6% and Xinlitai and Kelun Pharmaceutical dropping over 3.8% [1]. - The Hong Kong Stock Connect innovative drug ETF (520880) opened high but closed lower, with a decline of 1.58% and a trading volume of 335 million yuan [1]. - The ETF has seen continuous capital inflow for 13 days, totaling over 670 million yuan as of September 18 [3]. Group 2: Investment Opportunities - Despite short-term volatility, the long-term logic of the innovative drug sector remains intact, with no substantial negative news impacting the market [5]. - The current macroeconomic environment is favorable, with the Federal Reserve restarting its interest rate cut cycle, which may benefit the global pharmaceutical sector [5][6]. - The trend of innovative drugs is clear, with several products entering advanced negotiation stages for overseas markets, potentially leading to continuous cash flow [6]. Group 3: ETF Adjustments - The Hong Kong Stock Connect innovative drug ETF (520880) has undergone a "purification" revision, completely excluding CXO companies and focusing solely on innovative drug R&D firms [6][7]. - As of September 5, the ETF had achieved a year-to-date increase of 119.75%, outperforming other innovative drug indices [7][8]. - The ETF is the first in the market to track the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index, with a fund size exceeding 1.7 billion yuan and the highest liquidity among similar products [8].

Market Overview - The market experienced a day of low trading volume with major indices closing down, as total trading volume reached 2.35 trillion yuan, significantly lower than the previous day's 3.17 trillion yuan [1] - The Shanghai Composite Index fell by 1.3% for the week, while the Shenzhen Component Index rose by 1.14%, and the ChiNext Index increased by 2.34%, marking a seven-week consecutive rise [1] Sector Performance - The defense and military sector saw a notable rise, with Guorui Technology hitting the daily limit, and the Defense and Military ETF (512810) reaching a peak of 2% [1] - Real estate stocks showed volatility in the afternoon, with the real estate ETF (159707) rising by 2%, potentially driven by policy adjustments regarding property tax trials in Shanghai [1] - The non-ferrous metals sector rebounded significantly, with Ganfeng Lithium hitting the daily limit and the Non-ferrous Metals Leader ETF (159876) peaking at 1.7% [1] - Technology stocks displayed increased divergence, with the AI-focused ETFs showing mixed results; the Huabao ChiNext AI ETF (159363) rose by 0.58%, while the Huabao Sci-Tech AI ETF (589520) fell by 1.76% [1] Fund Flows - The top-tier brokerage ETF (512000) and the fintech ETF (159851) continued to decline, with respective decreases of 0.68% and 1.81%, despite strong fund inflows in previous days [2] - The top-tier brokerage ETF attracted 12.62 billion yuan in net inflows over the last 16 days, totaling 64.5 billion yuan [2] Hong Kong Market Dynamics - The Hong Kong market showed mixed performance, with the Hang Seng Index closing flat and the Hang Seng Tech Index slightly up by 0.37% [3] - The Hong Kong Internet ETF (513770) experienced volatility, initially rising by over 2% before closing up by 0.63% with a trading volume of 8.9 billion yuan [5] AI and Technology Sector Insights - The AI-driven technology sector remains a focal point, with significant growth potential as companies like Alibaba and Tencent continue to advance their AI capabilities [9] - The Hong Kong Internet ETF (513770) has outperformed the Hang Seng Tech Index, with a cumulative increase of over 15 percentage points [11] - The demand for AI computing power is expected to grow exponentially, with the global AI server market projected to reach 125.1 billion USD by 2024 [16] Innovation and Drug Development - The Hong Kong Innovation Drug ETF (520880) faced a decline, with a drop of 1.58% amid a broader market adjustment, but it has seen consistent inflows, totaling over 6.7 billion yuan in the past 13 days [22][23] - The ETF has been restructured to focus solely on innovative drug development, excluding CXO companies, which is expected to enhance its performance in the long run [23][24]